rs9923231 — VKORC1 -1639G>A
Warfarin sensitivity - determines initial dosing
Details
- Gene
- VKORC1
- Chromosome
- 16
- Risk allele
- A
- Consequence
- Regulatory
- Inheritance
- Codominant
- Clinical
- Risk Factor
- Evidence
- Established
- Chip coverage
- v3 v4 v5
Population Frequency
Ancestry Frequencies
Related SNPs
Category
PharmacogenomicsVKORC1 - The Warfarin Sensitivity Gene
VKORC111 Vitamin K Epoxide Reductase Complex Subunit 1 encodes the target enzyme
of warfarin. While CYP2C9 determines how quickly you metabolize warfarin, VKORC1
determines how sensitive your body is to it. Together, these two genes account for
about 40-50% of the variability in warfarin dose requirements between individuals,
with VKORC1 alone contributing approximately 30%22 approximately 30%
Rieder MJ et al. PNAS, 2005.
The Mechanism
The -1639G>A variant33 rs9923231 is in the promoter region of VKORC1 and affects
gene expression. The A allele reduces VKORC1 transcription by approximately
44% compared to the G allele44 44% compared to the G allele
measured by dual luciferase assay, producing
less target enzyme. Since warfarin works by inhibiting VKORC1, having less enzyme
means less warfarin is needed to achieve the same anticoagulant effect. This is why
A allele carriers are "sensitive" to warfarin - they need lower doses.
Warfarin Dose Ranges
The impact on dosing is substantial: - GG genotype: typically requires 5-7mg daily - AG genotype: typically requires 3-4mg daily - AA genotype: typically requires 1.5-2.5mg daily
These are rough ranges - actual doses also depend on CYP2C9 genotype, age, weight, interacting medications, and dietary vitamin K intake.
Population Variation
The VKORC1 -1639A allele shows dramatic worldwide variation55 worldwide variation
Ross KA et al. J Hum Genet, 2010:
approximately 90% frequency in East Asian populations, 38% in Europeans, and only
10% in African-descent populations. This largely explains the well-known observation
that East Asian patients typically need lower warfarin doses than European patients,
who in turn need lower doses than African-descent patients.
The Pharmacogenomic Success Story
Warfarin pharmacogenomics is one of the most validated applications of
personalized medicine. Multiple randomized controlled trials (including the
landmark EU-PACT66 EU-PACT
Pirmohamed M et al. A Randomized Trial of Genotype-Guided Dosing of Warfarin. N Engl J Med, 2013 and COAG77 COAG
Kimmel SE et al. A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing. N Engl J Med, 2013 trials) have demonstrated that genotype-guided warfarin
dosing reduces the time to stable therapeutic anticoagulation and decreases the
risk of both under- and over-anticoagulation during the critical initiation period.
Practical Implications
If you carry the A allele (AG or AA), you will need lower warfarin doses than average if ever prescribed this medication. This information should be in your medical record. While direct oral anticoagulants88 DOACs: newer blood thinners like apixaban and rivaroxaban that do not require genetic dose adjustment have replaced warfarin in many scenarios, warfarin remains the standard for mechanical heart valves and certain other conditions.
Drug Interactions
Genotype Interpretations
What each possible genotype means for this variant:
Normal warfarin sensitivity
You have normal VKORC1 expression. About 37% of Europeans share this genotype, though the frequency varies dramatically by ancestry. Standard warfarin dosing (typically starting around 5mg) is appropriate for you.
Increased warfarin sensitivity
You have one copy of the VKORC1 variant that reduces vitamin K cycling. About 47% of Europeans share this genotype. You'll need lower warfarin doses than average, typically around 3-4mg daily.
Highly sensitive to warfarin - low doses needed
You have two copies of the VKORC1 sensitivity variant. About 16% of Europeans share this genotype (much higher in East Asian populations where the AA genotype is the majority). You'll need substantially lower warfarin doses than average, often just 1-2mg daily.
Combined with CYP2C9 variants, your total dose reduction can be significant.
Key References
Pirmohamed et al. EU-PACT RCT of genotype-guided warfarin dosing vs standard dosing
Kimmel et al. COAG RCT comparing pharmacogenetic and clinical warfarin dosing algorithms
Johnson et al. CPIC guideline update for CYP2C9, VKORC1, CYP4F2 and warfarin dosing
Rieder et al. Effect of VKORC1 haplotypes on warfarin dose requirements
Ross et al. Worldwide allele frequency distribution of warfarin dose-related polymorphisms